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ABSTRACT  
Diabetes is the most prevalent disease in the world affecting middle and old aged 
persons of the world directly impacting their life style and other metabolic 
hazards. Karnim plus is a remedy of Unijules Life Sciences ltd. And current 
multicentric, randomized, single blind, active controlled and parallel group with 
metformin capsule clinical study is conducted in two centres of Dr. D.Y. Patil 
College and Ashwin Ayurved college respectively. Total 121 patients were treated 
according to the previously approved protocol from institutional ethics 
committee for the treatment period of 24 weeks in a dose of 2 capsules BID before 
meal and primary efficacy parameters set to HbA1c, fasting and post meal blood 
sugar. From the study it was concluded that Karnim plus capsule and Metformin 
capsule are equally effective in controlling hyperglycemia with slightly more time 
to achieve significance result in Karnim plus. In case of HbA1c highly significant 
results were observed in Karnim plus capsule and also highly significance is 
observed in symptom score of clinical parameters. Cholesterol levels are 
significantly decreased in Karnim plus group than metformin group. This 
indicated that Karnim plus is effective remedy in controlling diabetes type II with 
no any adverse effects and controlling metabolism in a effective way than other 
OHA. 
INTRODUCTION
The prevalence of NIDDM varies in different 
geographic regions and also in different ethnic 
groups [1]. The first authentic data on the prevalence 
of diabetes in India came from the multicentric 
study conducted by the Indian Council of Medical 
Research (ICMR) in the early seventies [2]. This 
study reported a prevalence of 2.3% in the urban 
and 1.5% in the rural areas. The criteria used in this 
study were different from those set by the WHO 
Expert Committee on Diabetes Mellitus. Many 
epidemiological studies carried out in different 
parts of the world reported an interesting finding 
that Indian migrants settled abroad had a high 
prevalence of NIDDM [3] which was believed to be 
due to greater affluence and a change to a more 
sedentary life style as compared to the native 
Indian population. However, the local host 
populations living in identical environment in these 
countries still had only a low prevalence rate of 
diabetes. Assuming that Indians as an ethnic group 
have a high degree of genetic predisposition to 
develop diabetes, one could expect higher 
prevalence of diabetes among the native urban 
populations with a comparable affluent life style. 
There is a vast difference in the percentages of 
subjects with known to unknown or undetected 
diabetes in urban and rural populations. The new to 
known ratio was 1:2 in an urban population while 
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the corresponding data for the rural population was 
3:1[4]. Similar findings have been reported for urban 
and rural populations of migrant Indians[5]. These 
differences are probably due to marked changes 
that have occurred in the quality of the food 
consumed. Urbanisation has probably led to a 
transition from consumption of natural form of food 
to a more refined food. This in combination with 
less physical activity could probably lead to 
unfavourable adiposity and hence increase the risk 
of developing diabetes. Factors influencing the 
prevalence of NIDDM Age and sex have been found 
to be the most positively associated parameters 
with NIDDM in both the urban and the rural 
populations surveyed in Madras [6]. The prevalence 
of diabetes was 41 % in the age group 55-64 years. 
It has been reported that in Southall, U.K., Asians 
aged 40-64 years had five times higher prevalence 
of diabetes as compared to the Europeans. Almost 
all the epidemiological studies have shown a male 
preponderance among the Indian diabetics inspite 
of increased rates of obesity in women. 
Studies in India indicate that more than 50% of 
people with diabetes have poor glycaemic control 
(HbA1c > 8%), uncontrolled hypertension and 
dyslipidaemia, and a large percentage have diabetic 
vascular complications.[7] 
Karnim plus capsule is a remedy of Unijules Life 
Sciences Ltd which has polyherbal combination of 
time tested herbs formulated in a standardized and 
advanced dosage form mainly acting on metabolic 
pathways. This is approved formulation by FDA. 
This study is randomized compared with active 
control group of Metformin capsule. This study is 
aimed to evaluate safety and efficacy w.r.t. glycemic 
control and metabolic control over patients of mild 
or moderate Diabetes mellitus type II 
MATERIALS AND METHODS 
This is a randomized, Single blind, Active controlled 
and parallel group controlled study about 
comparing efficacy and safety of Karnim plus 
capsules with active controlled group of Metformin 
capsules. 
This is a multicentric study conducted in two 
centres which is D.Y. Patil college of Ayurved, 
Hospital and research centre, Nerul, Mumbai, 
Maharashtra and Ashwin Ayurved college and 
hospital Manchi hill Sangamner Dist. Ahmadnagar 
Maharashtra. 
Proper Protocol and CRF (Case report form) was 
developed and presented to the Institutional ethics 
committee of both the study centres, necessary 
amendment were done as per the suggestions of EC 
and proper protocol of GCP (good clinical practices) 
is followed during the course of the study.  
All investigational medicinal products (IMP) i.e. 
Karnim plus capsules and Metformin capsules were 
provided to the study sites with proper packing and 
labelling by the company and audited by quality 
assurance department of Unijules life sciences ltd 
and from external clinical research auditor for 
compliance of protocol, patients recruited and 
source data verification. 
Patients were recruited from the OPD of both the 
study sites with following inclusive and exclusive 
criteria. 
Inclusion criteria 
Patients of either sex between the age group 18-75 
yrs both inclusive with a diagnosis of type II 
diabetes mellitus were selected for the study. 
Patients already taking Metformin. Patients must 
complete a study diary as instructed by doctor and 
staff and return the study diary as instructed by the 
study doctor. Patients must be willing and able to 
adhere to the protocol and No change in DM II 
treatment and no DM II-related hospital visits have 
been done during the past 3 weeks, were selected 
for the study. 
Exclusion criteria 
Patients of Type 1 diabetes. Patients having 
FBS>276 mg/dl at the time of screening. Patients 
having multiorgan involvement either Cardiac 
hepatic or renal. Diabetes that is a result of 
pancreatic injury, or secondary forms of diabetes. 
Evidence of serious diabetic complications. 
Laboratory value abnormalities as defined by the 
protocol. Has a history of hypersensitivity or allergy 
to Metformin, other DPP-4 inhibitors, or related 
compounds. Pregnancy induced DM type II. Serious 
secondary disorder like HIV, HBS Ag, Has history of 
cancer and those has any major illness or debility 
that in the investigator's opinion prohibits the 
subject from completing the study were excluded 
from the study. 
Objective and Efficacy parameters 
Primary objective of the study is to compare 
efficacy of Karnim plus capsule with control drug 
Metformin capsule and secondary objective is to 
assess comparative safety of karnim plus capsules 
with metformin capsules. For this following 
primary and secondary efficacy parameters were 
decided. 
Primary efficacy parameters were change in 
baseline values of HbA1c, fasting blood glucose 
(FBS) levels and post prandial (PP) blood glucose 
levels. Secondary efficacy parameters were change 
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in metabolic parameters like lipid profiles, and total 
and sub-domain scores of symptoms of diabetes i.e. 
polyuria, plyphasia, polydepsia etc. Symptoms 
scores assessed as a grade scale of 0 to 3 i.e. normal 
to sevior.  
Study procedure 
Patients complying to above mention inclusion 
criteria were included in the study and explained 
about the study drug, its effect, dosing schedule and 
they were provided with patient information shit 
and asked for signing a written informed consent 
form.  
After that patient went for screening period of 2 
days and treatment period of 24 weeks by the 
method of randomization to either treatment of 
Study drug (Karnim plus capsule) and control drug 
(Metformin capsule). The patients were advised to 
take medicines at a dose of 2 capsules with water 
15 min. Before meal. 
At screening visit detailed physical examination, 
vital signs and symptom scores were performed 
and documented by the investigator and blood 
collection were done for tests like blood sugar, 
HbA1c, CBC, LFT, KFT, Lipid profiles etc. After 2 
days all reports were analyzed and reviewed for 
eligibility of the patients for the study. Those who 
found eligible were selected for 24 weeks treatment 
period of either treatment of Karnim plus capsules 
(Group I) or Metformin capsules (Group II). 
Than follow-up visits were scheduled after every 
two weeks upto 24th week. During each visit 
physical examinations, vital signs and symptoms 
score were examined and documented in case 
report form as mentioned in protocol. HbA1c is 
checked before and after the treatment and fasting 
blood glucose (FBS) and post prandial (PP) blood 
glucose levels were assessed during each visit. A 
window period of +/- 2 days is allowed for the 
patient. During each visit checking of daily diary, 
use of rescue medication and compliance of 
medication was checked. 
 All adverse events were noted and recorded about 
nature and severity of the symptom, onset action, 
time to resolution of symptom. Patients were 
allowed to withdraw from the study at any time and 
any stage of the study. 
All data were complied and analyzed by using 
appropriate analytical test i.e. paired t test for 
grouped data and unpaired t test for comparing 
ungrouped data of group I and group II.  
RESULTS 
Total 256 patients were screened in both the study 
sites out of which 134 patients were enrolled for 
the 24 weeks treatment period. Out of these total 
122 patients have completed the total treatment 
period of 24 weeks. Total 61 patients in each group 
have completed the treatment period. 
In case of fasting blood sugar (FBS) which was 
primary efficacy parameter of the study, it was 
found that in treatment group I i.e. of Karnim plus 
capsule significant changes are observed after 4 
week of treatment. (Graph 1.1) After 2 week the 
values are decreased but these was not statistically 
significant. Where as in treatment group II i.e. of 
Metformin capsules it was observed that there was 
significant changes in FBS after 2 week of treatment 
and afterward in 4 week and further treatment 
course. This indicate that Karnim plus capsule is 
little slower in influencing blood glucose level as 
compared to metformin capsule but equally 
effective after 4 week of treatment. That may be 
because of herbal nature of the product, Karnim 
acts slowly and not as faster as metformin capule 
which is of synthetic nature. But this significancy is 
carried upto 24 weeks of treatment. 
In case of post meal blood sugar (PP) same kind of 
observations as like FBS was noted, (Graph 1.2) 
which confirms that Karnim plus capsules will 
require at least 4 week time to normalize blood 
sugar levels to be within the normal range. 
Interesting observations were noted in case of 
HbA1c. (Graph 1.3) Which was done before 
treatment and after 24 weeks of treatment. In case 
of Group I of Karnim plus capsules it shows highly 
significant decrease in before treatment and after 
treatment values whereas in trial group II 
significant decrease is noted. It proves that Karnim 
plus is slightly more effective than Metformin in 
controlling HbA1c i.e. glycocylated haemoglobin. 
This proves that in long therapy Karnim plus 
capsules has more impact over micro pathological 
levels than conventional OHA. Changes or 
correction at enzymatic level are more effective by 
the Karnim plus capsules. 
It was also observed that Cholesterol levels are 
significantly decreased after 24 weeks of treatment 
with Karnim plus capsules (Graph 1.4) whereas 
nonsignificant changes were observed in treatment 
with Metformin capsules. It again proves that 
Karnim plus is more effective in controlling 
metabolism and enzymatic changes within the 
digestive pathway. That may be because of 
polyherbal nature which has several herbs having 
proved action on the overall metabolic pathway. 
In case of clinical parameters, mean symptom score 
was analysed within the treatment weeks and 
within the two treatment groups also, which shows 
significant changes in polyurea (Graph 1.5), 
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polyphasia (Graph 1.6) and general weakness 
(Graph 1.7), after 4 weeks of treatment in group I 
(KPC) and after 8 weeks in treatment group II (MC). 
Which indicated that Karnim plus capsules is more 
effective in controlling associated secondary 
parameters of DM II than other OHA, which could 
be again due to polyherbal nature of the drug. 
In case of no. of patients in which urine sugar is 
present, (Table 1.1) significant results were noted 
in both the groups between before and after 
treatment and no significant difference are 
observed between group I and group II. 
Graph 1.1 
 
** Significant results observed in BT and AT in both the groups and non significant results within the two 
groups 
Graph 1.2 
 
** Significant results observed in BT and AT in both the groups and non significant results within the two 
groups 
Graph 1.3 
 
** Highly Significant results observed in BT and AT in Group I and significant in group II 
Graph 1.4 
 
** Highly Significant results observed in BT and AT in Group I and non significant in group II 
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Graph 1.5 
 
** Significant results were noted in group I after 4 week of treatment and non significant in group II after 4 
week but significant after 24 week 
Graph 1.6 
 
** Significant results were noted in group I after 24 week of treatment in group I and II 
Graph 1.7 
 
** Significant results were noted in group I after 4 week of treatment and non significant in group II after 4 
week but significant after 24 week 
Table 1.1  
** Highly Significant changes after 24 W of treatment in group I and group II 
DISCUSSION 
The prevalence of diabetes is rising all over the 
world due to population growth, aging, 
urbanisation and an increase of obesity and 
physical inactivity. Unlike in the West, where older 
persons are most affected, diabetes in Asian 
countries is disproportionately high in young to 
middle-aged adults. This could have long-lasting 
adverse effects on a nation’s health and economy, 
especially for developing countries. The 
International Diabetes Federation (IDF) estimates 
the total number of people in India with diabetes to 
be around 50.8 million in 2010, rising to 87.0 
million by 2030. The primary goal in the 
management of diabetes mellitus is the attainment 
of near-normal glycaemia. In India, more than half 
of patients have poor glycaemic control and have 
vascular complications. Therefore, there is an 
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KPC treated (Group I) Present 50 15 8 4** 
Absent 11 46 53 57 
MC treated (Group II) Present 55 20 7 3** 
Absent 6 41 54 58 
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urgent need to develop novel therapeutic agents of 
diabetes without the development and progression 
of complications or compromising on safety. 
'KARNIM PLUS®' is a formulation (Table 1.1) 
composed of medicinal herbs with proven 
pharmacological actions, which take care of all 
major complication of diabetes. The pharma-
cological action of individual herbs indicates that 
the major ingredients of 'KARNIM PLUS' are as 
follows Karela (Momordica charantia) has been 
found effective in lowering the blood glucose in 
man. The anti-diabetic activity of M. charantia is 
due to two active ingredients, Polypeptide -P and 
Charantin. Polypeptide -P is a 17 amino acid 
polypeptide, 16 of which are similar to crystalline 
insulin of bovine origin. This polypeptide has been 
shown to be ' insulinomimetic.' A number of other 
polypeptides from M. charantia seeds have been 
studied in vivo for the insulin like activities of 
stimulation of lipogenesis and inhibition of 
corticotropin-induced lipolysis. The mechanism 
was suggested to involve interaction of peptides 
with -adrenergic or corticotropin receptors. The 
other active constituent, charantin is a mixture of 
two steroid glycosides: -sitosterol-D-glucoside 
and 5,25-stigmastadien-3--ol-D-glucoside. Studies 
performed in vitro with M. charantia fruit extracts 
indicated a significant enhancement of glucose 
uptake in muscle tissue and of glycogen 
accumulation in muscles and hepatic tissue but no 
effect on glucose uptake or triglyceride synthesis in 
adipose tissue. Inhibition of glucose uptake by 
intestinal fragments was also observed and 
attributed to glycosidic constituent of the fruit 
extract. M. charantia has been demonstrated to 
possess a dose dependent increase in the 
scavenging activity against superoxide radical and 
hydroxyl radicals. M. charantia is a potent 
scavenger of superoxide and Hydroxy radicals. The 
antidiabetic effect of the plant is mediated through 
oxygen radical scavenging mechanism. Indeed the 
body itself possess enzymes such as Superoxide 
dismutase which routinely protects the -cells in 
pancreas through their scavenging action. The free 
radical scavenging antidiabetic role of M. charantia 
supports an additional prophylactic role as many 
diabetogenic chemicals such as Alloxan, 
Streptozotocin, Pyrinuron, Food nitrosoamines, 
cynogenic glycosides such as Linamarin and other 
sources of Dietary cyanide induce diabetes through 
damage to pancreatic -cells via free radical 
generation. Thus it appears that therapeutic 
activity of M. charantia against diabetes is due to 
pancreatic, extra-pancreatic and pancreas- 
protective properties. Neem (Azadirachta indica) 
has been demonstrated to exert hypoglycemic 
effect in streptozotocin induced diabetes. It shows 
its anti-diabetic action by stimulating the insulin 
secretion by the  cells of Islets of Langerhans of 
the pancreas in a manner similar to the sulfonyl 
ureas like chlorpropamide. Recurrent infections 
due to high blood glucose levels and slowed down 
immune responses due to gradual deterioration of 
immune system because of loss of body proteins is 
a common feature in diabetes. A. indica has been 
demonstrated to induce production of interleukin 
by stimulating specific types of T-cells of the 
immune system, the lack of which is a common 
feature of diabetes. So it can be said that A. indica 
enhances cell-mediated immune responses and 
thus can normalize the deteriorating immune 
system in diabetes. Ocimum sanctum (Tulsi) 
promotes uptake of glucose by peripheral tissue 
most likely by decreasing peripheral resistance to 
insulin. O. sanctum has been demonstrated to 
reduce blood glucose level in diabetic rats and also 
to promote action of other diabetic medications 
including oral hypoglycemics and exogenous 
insulin. O. sanctum is also effective in aggravated 
hyperglycemia precipitated by stress by virtue of 
its capacity to normalise stress induced 
neurological changes. O. sanctum has been 
demonstrated to have a normalizing effect on the 
levels of adrenaline, noradrenaline and monoamine 
oxidase which are generally decreased in stressed 
condition and thereby help the body to cope better 
with stress induced hyperglycemia.  
Picrorrhiza kurroa (Kutki): is useful in treating 
hyperglycemia. The anti-hyperglycemic activity 
attributed to the bitter principle 'kutkin'. This 
principle is known to stimulate secretion of gastrin, 
secretin and cholecystokinin pancreazymin which 
then stimulate secretion of insulin by -cells of 
pancreas. Beside anti-hyperglycemic activity, P. 
kurroa also possess immunomodulator and hepato-
protective activity. The iroid glycoside fraction of 
the herb is responsible for the immunostimulation 
and is capable of inducing both antigen-specific and 
non-specific responses. Thus P. kurroa helps to 
potentiate the body's immune responses which are 
usually diminished in diabetes. Increased 
glycogenolysis and decreased gluconeogenesis in 
liver due to dysfunctioning of insulin dependent 
metabolic pathways is a characteristic feature of 
diabetes. This affects normal functioning of liver 
ultimately disrupting the metabolic balance of body 
and may lead to life threatening conditions like 
ketosis and acidosis. P. kurroa has been 
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demonstrated to posses hepato-protective action 
and normalizes the functioning of liver due to 
presence of active ingredients Picrosides I and II 
which are glycosidic in nature. So besides lowering 
blood glucose hepatoprotection in diabetes is an 
added advantage of P. kurroa. Zingiber officinale 
(Sounth) exerts its anti-hyperglycemic effect by 
stimulating the  cells to secrete insulin. This action 
is attributed to its active constituents 6,8 and 10 
gingerols which cause inhibition of Na+/ K+ pump. 
Reduced potassium conductance causes membrane 
depolarisation and influx of Ca++ ions through 
voltage sensitive Ca++ channels which ultimately 
stimulates insulin secretion by  cells of pancreas. 
Elevated fatty acid level and onset of athero-
sclerosis is a common feature in diabetes due to 
increased lipolysis. Z. officinale is effective in 
lowering blood lipid levels and thus circumvents 
the danger of development of atherosclerosis in 
diabetic patients.  
CONCLUSION 
From the above mentioned results following 
conclusion can be drawn Karnim plus capsule and 
Metformin capsule is equally effective in controlling 
blood sugar levels, i.e. they have equal anti-
hyperglycemic effect on the patients of Diabetis 
Mellitus type II. Significant antihyperglycemic effect 
of Karnim plus capsule will be observed after at 
least 4 weeks of treatment which will be sustained 
in due course of treatment. Considering better 
effect over HbA1c and cholesterol it can be 
concluded that Karnim plus capsule has more 
potent metabolic effect than Metformin capsule. 
From the above study it is concluded that herbal 
treatment of Karnim is equally beneficial to 
patients of DM II for controlling blood sugar level 
and rather more effective in controlling other 
associated clinical parameters and overall digestion 
and metabolism of an individual. Treatment of 
Karnim plus capsule for patients of DM II is 
completely safe and non hazardous. It has good 
adaptability, convenience dosing, and good 
assimilation through the gut flora. 
It doesn’t produce any untoward significant 
changes in LFT and KFT profiles. Patients with 
newly diagnosed type II DM can be safely given 
treatment with Karnim capsules alone. However, a 
larger clinical trial is proposed to evaluate its 
efficacy in a wider perspective.  
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